<DOC>
	<DOCNO>NCT00297271</DOCNO>
	<brief_summary>The purpose PRIME Study examine current management outcome patient mild cognitive impairment dementia . Approximately 4500 patient enrol disease registry across 12 site Australia . Clinical , treatment , health status economic data acquire 3 year . The study identify relationship among demographic variable , prognostic feature , geographic setting , treatment option clinical , economic health status ( activity daily live caregiver impact ) outcomes .</brief_summary>
	<brief_title>Prospective Research Memory Clinics ( PRIME )</brief_title>
	<detailed_description>A complete record patient care collect provide detailed information management outcome mild cognitive impairment dementia profile patient participate site . The data use build model look effect management condition principal clinical event , health status economic outcome . This provide foundation subsequent objective prospective evaluation evidence-based strategy optimal treatment mild cognitive impairment dementia Australia . This study prescriptive , instead examine influence whole range routinely used management strategy clinical economic outcome among mild cognitive impaired dementia patient Australia . This 'practice base ' approach increasingly widely use useful tool elucidate relative effectiveness different management strategy explore relationship patient characteristic , treatment outcome . Observational study - study drug administer .</detailed_description>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Diagnosis dementia DSMIV criterion , Mild Cognitive Impairment , use Peterson Criteria Living community ( home , apartment collective housing nursing care available le 40 hour per week ) Patient able provide write informed consent , provision write informed consent legal guardian/proxy Availability caregiver willing provide consent require component study Fluent English May participate Phase IV postmarketing follow study approve product treatment dementia No concomitant lifethreatening illness ( condition likely interfere patient 's ability complete study ) Not unwilling unable complete study Not concurrently participate clinical trial investigational drug ( phase I , II III ) Unwillingness patient legal guardian / proxy provide write informed consent Unwillingness caregiver provide write informed consent For patient diagnosis mild cognitive impairment : current previous treatment cholinesterase memantine</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Mild Cognitive Impairment</keyword>
	<keyword>Patient Registries</keyword>
	<keyword>Prospective Studies</keyword>
	<keyword>Longitudinal Studies</keyword>
	<keyword>Australia</keyword>
	<keyword>Cholinesterase Inhibitors</keyword>
	<keyword>Observational</keyword>
	<keyword>Non-randomized</keyword>
</DOC>